This disclosure provides compositions, systems, and methods for the delivery of therapeutic oligonucleotides to a tumor. The oligonucleotide is conjugated to a dendron comprising an end group, a phosphate group, and/or a hydrophobic chain.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
This disclosure provides compositions, systems, and methods for the delivery of therapeutic oligonucleotides to the lung. The oligonucleotide is conjugated to a dendron comprising a hydrophilic end group, a phosphate group, and/or a hydrophobic chain.
A61K 47/56 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
3.
DENDRITIC CONJUGATES FOR THE BRAIN DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES
This disclosure provides compositions, systems, and methods for the delivery of therapeutic oligonucleotides to the brain. The oligonucleotide is conjugated to a dendron comprising a hydrophilic end group, a phosphate group, and/or a hydrophobic chain.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
4.
DENDRITIC CONJUGATES FOR THE SKIN DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES
This disclosure provides compositions, systems, and methods for the delivery of therapeutic oligonucleotides to the skin. The oligonucleotide is conjugated to a dendron comprising a hydrophilic end group, a phosphate group, and/or a hydrophobic chain.
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
6.
DENDRITIC CONJUGATES FOR THE BRAIN DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES
This disclosure provides compositions, systems, and methods for the delivery of therapeutic oligonucleotides to the brain. The oligonucleotide is conjugated to a dendron comprising a hydrophilic end group, a phosphate group, and/or a hydrophobic chain.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
This disclosure provides compositions, systems, and methods for the delivery of therapeutic oligonucleotides to a tumor. The oligonucleotide is conjugated to a dendron comprising an end group, a phosphate group, and/or a hydrophobic chain.
This disclosure provides compositions, systems, and methods for the delivery of therapeutic oligonucleotides to the lung. The oligonucleotide is conjugated to a dendron comprising a hydrophilic end group, a phosphate group, and/or a hydrophobic chain.
This disclosure provides compositions, systems, and methods for the delivery of therapeutic oligonucleotides to the skin. The oligonucleotide is conjugated to a dendron comprising a hydrophilic end group, a phosphate group, and/or a hydrophobic chain.
Conjugated nucleic acid molecules and methods are provided for delivery of a therapeutic oligonucleotide. The therapeutic oligonucleotide is bonded to a nucleic acid strand having a polyadenine segment that forms a supramolecular polymer with a thymine-mimicking compound. The supramolecular polymer is configured to dissociate to release the therapeutic oligonucleotide and grant it nuclease resistance. Nuclease resistance applies sequences adjacent to the polyadenine/thymine-mimicking assembly.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
12.
MARKERS TO PREDICT MACROCYCLIC LACTONE DRUG RESISTANCE IN DIROFILARIA IMMITIS, THE CAUSATIVE AGENT OF HEARTWORM DISEASE
Disclosed are nucleic acid molecules from the genome of Dirofilaria spp. nematodes that contain single nucleotide polymorphisms related to reduced responsiveness of the nematodes to macrocyclic lactones. In one example, the species of Dirofilaria is Dirofilaria immitis (the agent of heartworm in animals). Also disclosed are methods for determining the responsiveness of Dirofilaria spp. nematodes to macrocyclic lactones, methods for selecting a treatment to treat an animal infected with Dirofilaria spp. nematode, and kits for determining the responsiveness of Dirofilaria spp. nematodes to macrocyclic lactones.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
13.
DEEP LEARNING BASED PREDICTION OF FABRICATION-PROCESS-INDUCED STRUCTURAL VARIATIONS IN NANOPHOTONIC DEVICES
A computer-implemented method comprising the steps of: with an imaging device, acquiring a plurality of images of structures of a fabricated device; preprocessing the plurality of images; creating at least one image dataset from the preprocessed plurality of images; generating a predictor model; training the predictor model with the at least one image dataset to identify structural features of the fabricated device with a propensity for fabrication anomalies.
G06V 10/70 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning
B82Y 40/00 - Manufacture or treatment of nanostructures
G01N 23/2251 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by measuring secondary emission from the material using electron or ion microprobes using incident electron beams, e.g. scanning electron microscopy [SEM]
G01N 37/00 - Details not covered by any other group of this subclass
G06F 30/398 - Design verification or optimisation, e.g. using design rule check [DRC], layout versus schematics [LVS] or finite element methods [FEM]
A computer-implemented method comprising the steps of: with an imaging device, acquiring a plurality of images of structures of a fabricated device; preprocessing the plurality of images; creating at least one image dataset from the preprocessed plurality of images; generating at least one of a predictor model and a corrector model; training the predictor model with the at least one image dataset to identify structural features of the fabricated device with a propensity for fabrication deviations, wherein the corrector model is useful for completing tasks comprising of at least: receiving a desired layout as input and generating a layout output, and automatically correcting the device design to minimize the impact of fabrication deviations on its operation.
A method and apparatus of early-stage detection of glaucoma and other optic nerve or retinal diseases employs dynamic images that are processed differently by Y-like cells and X-like cells to provide a sensitive detection of early Y-like cell impairment which provides early indications of glaucoma isolated from non-specific information from X-like cells.
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
16.
APPARATUS FOR DETECTION OF EARLY-STAGE GLAUCOMA AND OTHER OPTIC NERVE DISEASES
A method and apparatus of early-stage detection of glaucoma and other optic nerve or retinal diseases employs dynamic images that are processed differently by Y-like cells and X-like cells to provide a sensitive detection of early Y-like cell impairment which provides early indications of glaucoma isolated from non-specific information from X-like cells.
A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
17.
System and method for estimating synthetic quantitative health values from medical images
A computer-implemented method, an apparatus, and a system for estimating synthetic values of quantitative metrics are provided. They involve calculating new, more accurate boundaries using a classifier based on local intensity and spatial estimators, for the segmentation mask provided by a non-local means patch-based segmentation in a test image, and estimating for the pixels of interest at least one synthetic value of a quantitative metric using a given value of the quantitative metric assigned to the reference images and the boundaries. The method, apparatus, and system provide the advantage of generating synthetic values directly comparable against known values for given subjects or against predetermined scales for diagnostic or prognostic purposes. In the specific case of Alzheimer's disease, the invention stretches the predictive range up to two full decades, which constitutes a significant advance in the field of medical diagnostics.
G06T 7/174 - SegmentationEdge detection involving the use of two or more images
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G06K 9/46 - Extraction of features or characteristics of the image
G06K 9/62 - Methods or arrangements for recognition using electronic means
The present invention relates to maresins, preferably maresin-1, for use in the treatment of CNS injuries preferably selected from spinal cord injury and traumatic brain injury.
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
A61K 31/232 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
The present invention relates to maresins, preferably maresin-1, for use in the treatment of CNS injuries preferably selected from spinal cord injury and traumatic brain injury.
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
A61K 31/232 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
20.
DECONSTRUCTION OF OILSAND MATERIALS USING IONIC LIQUIDS
In alternative aspects, the invention provides process for the use of ionic liquids in the remediation and amelioration of oilsand materials, including treatment of tailings products including but not limited to mature fine tailings (MFT), separation of bitumen from oilsand, bitumen transportation, remediation of spilled bitumen and dilbit, treatment (breakage) of steam assisted gravity drainage (SAGD) and heavy oil emulsions, solids removal from oil processing streams, in-situ bitumen recovery, in-situ extraction from mineral reservoirs, production well chemicals, CO2 sequestration and fracking fluids.
C10G 1/04 - Production of liquid hydrocarbon mixtures from oil shale, oil-sand, or non-melting solid carbonaceous or similar materials, e.g. wood, coal by extraction
C02F 1/00 - Treatment of water, waste water, or sewage
C02F 1/26 - Treatment of water, waste water, or sewage by extraction
C02F 1/38 - Treatment of water, waste water, or sewage by centrifugal separation
C02F 1/48 - Treatment of water, waste water, or sewage with magnetic or electric fields
C10G 33/04 - De-watering or demulsification of hydrocarbon oils with chemical means
C10G 75/02 - Inhibiting corrosion or fouling in apparatus for treatment or conversion of hydrocarbon oils, in general by addition of corrosion inhibitors
21.
SYSTEM AND METHOD FOR ESTIMATING SYNTHETIC QUANTITATIVE HEALTH VALUES FROM MEDICAL IMAGES
A computer-implemented method, an apparatus, and a system for estimating synthetic values of quantitative metrics are provided. They involve calculating new, more accurate boundaries using a classifier based on local intensity and spatial estimators, for the segmentation mask provided by a non- local means patch-based segmentation in a test image, and estimating for the pixels of interest at least one synthetic value of a quantitative metric using a given value of the quantitative metric assigned to the reference images and the boundaries. The method, apparatus, and system provide the advantage of generating synthetic values directly comparable against known values for given subjects or against predetermined scales for diagnostic or prognostic purposes. In the specific case of Alzheimer's disease, the invention stretches the predictive range up to two full decades, which constitutes a significant advance in the field of medical diagnostics.
A computer-implemented method, an apparatus, and a system for estimating synthetic values of quantitative metrics are provided. They involve calculating new, more accurate boundaries using a classifier based on local intensity and spatial estimators, for the segmentation mask provided by a non- local means patch-based segmentation in a test image, and estimating for the pixels of interest at least one synthetic value of a quantitative metric using a given value of the quantitative metric assigned to the reference images and the boundaries. The method, apparatus, and system provide the advantage of generating synthetic values directly comparable against known values for given subjects or against predetermined scales for diagnostic or prognostic purposes. In the specific case of Alzheimer's disease, the invention stretches the predictive range up to two full decades, which constitutes a significant advance in the field of medical diagnostics.
H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
This invention relates to systems and methods for measuring quantitatively multiple species or heavy metals, including mercury, and other toxic pollutants. More specifically, the systems and methods of the invention allows for determination of the analytes even at very low concentration, through concentration on a collection interface, desorption and analysis by mass spectrometry. The invention also provides for a portable device or kit for modifying an existing mass spectrometer.
H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locksArrangements for external adjustment of electron- or ion-optical components
H01J 49/00 - Particle spectrometers or separator tubes
A triazole bridged flavonoid dimer compound library was efficiently constructed via the cycloaddition reaction of a series of flavonoid-containing azides (Az 1-15) and alkynes (Ac 1-17). These triazole bridged flavonoid dimers and their precursor alkyne- and azide-containing flavonoids were screened for their ability to modulate multidrug resistance (MDR) in P-gp-overexpressed cell line (LCC6MDR), MRP1-overexpressed cell line (2008/MRP1) and BCRP-overexpressed cell line (HEK293/R2 and MCF7-MX100). Generally, they displayed very promising MDR reversal activity against P-gp-, MRP1- and BCRP-mediated drug resistance. Moreover, they showed different levels of selectivity for various transporters. Overall, they can be divided into mono-selective, dual-selective and multi-selective modulators for the P-gp, MRP1 and BCRP transporters. The EC50 values for reversing paclitaxel resistance (141-340 nM) of LCC6MDR cells, DOX (78-590 nM) and vincristine (82-550 nM) resistance of 2008/MRP1 cells and topotecan resistance (0.9-135 nM) of HEK293/R2 and MCF7-MX100 cells were at nanomolar range. Importantly, a number of compounds displayed EC50 at or below 10 nM in BCRP-overexpressed cell lines, indicating that these bivalent triazoles more selectively inhibit BCRP transporter than the P-gp and MRP1 transporters. Most of the dimers are notably safe MDR chemosensitizers as indicated by their high therapeutic index values.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
28.
MARKERS TO PREDICT MACROCYCLIC LACTONE RESISTANCE IN DIROFILARIA IMMITIS, THE CAUSATIVE AGENT OF HEARTWORM DISEASE
Disclosed are nucleic acid molecules from the genome of Dirofilaria spp. nematodes that contain single nucleotide polymorphisms related to reduced responsiveness of the nematodes to macrocyclic lactones. In one example, the species of Dirofilaria is Dirofilaria immitis (the agent of heartworm in animals). Also disclosed are methods for determining the responsiveness of Dirofilaria spp. nematodes to macrocyclic lactones, methods for selecting a treatment to treat an animal infected with a Dirofilaria spp. nematode, and kits for determining the responsiveness of Dirofilaria spp. nematodes to macrocyclic lactones.
Disclosed are nucleic acid molecules from the genome of Dirofilaria spp. nematodes that contain single nucleotide polymorphisms related to reduced responsiveness of the nematodes to macrocyclic lactones. In one example, the species of Dirofilaria is Dirofilaria immitis (the agent of heartworm in animals). Also disclosed are methods for determining the responsiveness of Dirofilaria spp. nematodes to macrocyclic lactones, methods for selecting a treatment to treat an animal infected with a Dirofilaria spp. nematode, and kits for determining the responsiveness of Dirofilaria spp. nematodes to macrocyclic lactones.
Disclosed are nucleic acid molecules from the genome of Dirofilaria spp. nematodes that contain single nucleotide polymorphisms related to reduced responsiveness of the nematodes to macrocyclic lactones. In one example, the species of Dirofilaria is Dirofilaria immitis (the agent of heartworm in animals). Also disclosed are methods for determining the responsiveness of Dirofilaria spp. nematodes to macrocyclic lactones, methods for selecting a treatment to treat an animal infected with a Dirofilaria spp. nematode, and kits for determining the responsiveness of Dirofilaria spp. nematodes to macrocyclic lactones.
Disclosed are 5'-triposphate oligoribonucleotides, pharmaceutical compositions comprising said 5'-triposphate oligoribonucleotides, and methods of using said 5'-triposphate oligoribonucleotides to treat viral infections.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
34.
LAYERED AND SPINEL LITHIUM TITANATES AND PROCESSES FOR PREPARING THE SAME
The present invention relates to a process for producing lithium titanate which includes the steps of synthesizing a lithium titanate hydrate intermediate via The present invention relates to a process for producing lithium titanate which includes the steps of synthesizing a lithium titanate hydrate intermediate via aqueous chemical processing, and thermally treating the lithium titanate hydrate intermediate to produce the lithium titanate. The lithium titanate hydrate is preferably (Li1.81Ho.19)Ti20.«2H20. The lithium titanate is preferably Li4Ti5012 (LTO). Synthesizing the lithium titanate hydrate intermediate may include mixing a titanium-containing compound with a lithium- containing compound in a solvent to produce a lithium-titanium precursor mixture. Preferably the titanium-containing compound comprises titanium tetrachloride TiCI4. The invention also relates to a lithium titanate obtained according to the process and a lithium battery comprising the lithium titanate.
C01D 13/00 - Compounds of sodium or potassium not provided for elsewhere
H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
35.
LAYERED AND SPINEL LITHIUM TITANATES AND PROCESSES FOR PREPARING THE SAME
The present invention relates to a process for producing lithium titanate which includes the steps of synthesizing a lithium titanate hydrate intermediate via The present invention relates to a process for producing lithium titanate which includes the steps of synthesizing a lithium titanate hydrate intermediate via aqueous chemical processing, and thermally treating the lithium titanate hydrate intermediate to produce the lithium titanate. The lithium titanate hydrate is preferably (Li1.81Ho.19)Ti20.«2H20. The lithium titanate is preferably Li4Ti5012 (LTO). Synthesizing the lithium titanate hydrate intermediate may include mixing a titanium-containing compound with a lithium- containing compound in a solvent to produce a lithium-titanium precursor mixture. Preferably the titanium-containing compound comprises titanium tetrachloride TiCI4. The invention also relates to a lithium titanate obtained according to the process and a lithium battery comprising the lithium titanate.
H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
C01D 13/00 - Compounds of sodium or potassium not provided for elsewhere
36.
Biomaterial of chymotryptically isolated fraction of fibroin in a hydrogel
THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING (USA)
MCGILL UNIVERSITY (USA)
Inventor
Nazhat, Showan N.
Marelli, Benedetto
Freddi, Giuliano
Alessandrino, Antonio
Barralet, Jake E.
Abstract
A method for making a biomaterial comprising providing at least one polypeptide fraction chymotryptically isolated and extracted from fibroin, and adding the at least one extracted polypeptide fraction to a hydrogel precursor before gelling, wherein the at least one isolated and extracted polypeptide fraction is selected from a soluble fraction Cs, and a precipitated fraction Cp. A biomaterial comprising at least one of the isolated and extracted polypeptide fractions incorporated in a hydrogel or a hydrogel precursor. Use of the biomaterial for constructing, regenerating, repairing, replacing or augmenting soft or hard tissue; as an in vitro or in vivo construct; as a coating material; or as a cell, molecule or particle delivery medium. Use of the isolated and extracted polypeptide fraction Cs for promoting osteoinduction, osteoconduction or osteogenesis. Use of the isolated and extracted polypeptide fraction Cp for enhancing a mechanical compressive modulus of a material into which it is incorporated.
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
A triazole bridged flavonoid dimer compound library was efficiently constructed via the cycloaddition reaction of a series of flavonoid-containing azides (Az 1-15) and alkynes (Ac 1-17). These triazole bridged flavonoid dimers and their precursor alkyne- and azide-continaing flavonoids were screened for their ability to modulate multidrug resistance (MDR) in P-gp-overexpressed cell line (LCC6MDR), MRPl-overexpressed cell line (2008/MRPl) and BCRP-overexpressed cell line (HEK293/R2 and MCF7-MX100). Generally, they displayed very promising MDR reversal activity against P-gp-, MRPl- and BCRP-mediated drug resistance. Moreover, they showed different levels of selectivity for various transporters. Overall, they can be divided into mono-selective, dual-selective and multi-selective modulators for the P-gp, MRPl and BCRP transporters. The EC50 values for reversing paclitaxel resistance (141 - 340 nM) of LCC6MDR cells, DOX (78 - 590 nM) and vincristine (82 - 550 nM) resistance of 2008/MRPl cells and topotecan resistance (0.9 - 135 nM) of HEK293/R2 and MCF7-MX100 cells were at nanomolar range. Importantly, a number of compounds displayed EC50 at or below 10 nM in BCRP-overexpressed cell lines, indicating that these bivalent triazoles more selectively inhibit BCRP transporter than the P-gp and MRPl transporters. Most of the dimers are notably safe MDR chemosensitizers as indicated by their high therapeutic index values.
C07D 311/30 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
C07D 311/32 - 2, 3-Dihydro derivatives, e.g. flavanones
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
The invention relates to oligonucleotides having alternating segments of sugar-modified nucleosides and 2′-deoxynucleosides, and uses thereof. The invention further related to oligonucleotides having alternating segments of sugar-modified nucleotides and 2′-deoxynucleotides, and uses thereof. Such uses include the preparation of antisense oligonucleotides and their use for the prevention or depletion of function of a target nucleic acid of interest, such as an RNA, in a system. Accordingly, and oligonucleotide of the invention is useful for therapeutic, analytical and diagnostic methods and uses, as well as component of compositions and commercial packages corresponding to such methods and uses.
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
The Administrators of the Tulane Educational Fund (USA)
McGill University (Canada)
Inventor
Bowers, Cyril Y.
Coy, David H.
Hocart, Simon J.
Tannenbaum, Gloria S.
Abstract
The present invention provides novel peptides that can modulate the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and sub-types, isoforms and variants thereof). These peptides are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperpro-liferative disorders.
Applicants have discovered a new low-cost and accessible method and apparatus that allowing for quicker and more precise state determinations based on medical images. The method and apparatus are non-intrusive and require providing a medical image of a subject and determining a state based on a comparison to a training image set comprising two or more states. There is provided, according to the present invention, a computer-implemented method for processing medical images comprising calculating non-local means patch-based weights comparing patches surrounding pixels of interest in a test image with a number of patches of pixels surrounding a corresponding number of pixels in reference images; and calculating for the pixels of interest at least one state estimation using a given state assigned to said reference images and said weights.
Applicants have discovered an innovative approach to robustly and accurately detect Alzheimer's disease (AD) and prodromal forms of AD based on the distinction of specific atrophic patterns of anatomical structures such as hippocampus (HC) and entorhinal cortex (EC) in regions of interest of an image. The discovery allows to efficiently determine a pathological status and grading of pixels of interest when compared (weighed) to images from a reference library having pre-defined states. The discovery simultaneously performs segmentation and grading of structures to efficiently capture the anatomical alterations caused by AD. Based on a nonlocal patch- based framework, the grading measure estimates the similarity of the patch surrounding the voxel under study with all the patches present in different training populations.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
Applicants have discovered an innovative approach to robustly and accurately detect Alzheimer's disease (AD) and prodromal forms of AD based on the distinction of specific atrophic patterns of anatomical structures such as hippocampus (HC) and entorhinal cortex (EC) in regions of interest of an image. The discovery allows to efficiently determine a pathological status and grading of pixels of interest when compared (weighed) to images from a reference library having pre-defined states. The discovery simultaneously performs segmentation and grading of structures to efficiently capture the anatomical alterations caused by AD. Based on a nonlocal patch-based framework, the grading measure estimates the similarity of the patch surrounding the voxel under study with all the patches present in different training populations.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
INNOVHUB-STAZIONI SPERIMENTALI PER L'INDUSTRIA (Italy)
Inventor
Nazhat, Showan, N.
Marelli, Benedetto
Barralet, Jake, E.
Freddi, Giuliano
Alessandrino, Antonio
Abstract
A method for making a biomaterial comprising providing at least one polypeptide fraction chymotryptically isolated and extracted from fibroin, and adding the at least one extracted polypeptide fraction to a hydrogel precursor before gelling, wherein the at least one isolated and extracted polypeptide fraction is selected from a soluble fraction Cs, and a precipitated fraction Cp. A biomaterial comprising at least one of the isolated and extracted polypeptide fractions incorporated in a hydrogel or a hydrogel precursor. Use of the biomaterial for constructing, regenerating, repairing, replacing or augmenting soft or hard tissue; as an in vitro or in vivo construct; as a coating material; or as a cell, molecule or particle delivery medium. Use of the isolated and extracted polypeptide fraction Cs for promoting osteoinduction, osteoconduction or osteogenesis. Use of the isolated and extracted polypeptide fraction Cp for enhancing a mechanical compressive modulus of a material into which it is incorporated.
C08L 89/00 - Compositions of proteinsCompositions of derivatives thereof
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
C09D 189/00 - Coating compositions based on proteinsCoating compositions based on derivatives thereof
C12P 21/06 - Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 17/04 - Peptides being immobilised on, or in, an organic carrier entrapped within the carrier, e.g. gel, hollow fibre
44.
BIOACTIVE PEPTIDES AND PROTEINS CONTAINING BIOACTIVE PEPTIDES, THEIR USES AND PROCESSES FOR MAKING THE SAME
A process for treating a protein before hydrolytic digestion, the process comprising exposing the protein to at least one cycle of microwave irradiation to produce a microwave treated protein containing one or more bioactive peptides. Further hydrolyzing the microwave treated protein to release at least one of the one or more bioactive peptides. A pharmaceutical composition, supplement and food product including the microwave treated protein or the one or more released bioactive peptides.
C12P 21/06 - Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
A23C 9/127 - Fermented milk preparationsTreatment using microorganisms or enzymes using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss
A23J 1/00 - Obtaining protein compositions for foodstuffsBulk opening of eggs and separation of yolks from whites
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (USA)
MCGILL UNIVERSITY (Canada)
Inventor
Bowers, Cyril Y.
Coy, David H.
Hocart, Simon J.
Tannenbaum, Gloria S.
Abstract
The present invention provides novel peptides that can modulate the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). These peptides are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperproliferative disorders.
The present invention provides various compounds, compositions, and methods. In some embodiments, provided compounds have activity as, for example, inhibitors of protein translation.
C07D 307/93 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
C07D 307/77 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
C07D 407/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
The present invention relates to a method for determining the ideal time for and outcome of reproductive health procedures including in vitro fertilization by establishing a correlation between the successful outcome of said procedure and the spectra of a body fluid obtained using a chosen analytical modality for a population of patients, acquiring for a patient a spectrum of the body fluid of the patient using said chosen modality.
There is described an optical waveguide structure exhibiting nonlinear properties, a method of fabricating such, and an optical coupling device made of two of such optical waveguide structures. The optical waveguide structure comprises an optical waveguide portion made of a light transmitting material for supporting a light mode traveling therein. The light transmitting material has an intrinsic nonlinearity parameter suitable for inducing a nonlinearity on the light mode, and the optical waveguide portion having a diameter sized to securely confine the light mode therein and to increase the nonlinearity on the light mode. The optical waveguide structure also has a coating surrounding the optical waveguide portion to mechanically support or to protect the optical waveguide portion from surface damage.
This invention relates to systems and methods for measuring quantitatively multiple species or heavy metals, including mercury, and other toxic pollutants. More specifically, the systems and methods of the invention allows for determination of the analytes even at very low concentration, through concentration on a collection interface, desorption and analysis by mass spectrometry. The invention also provides for a portable device or kit for modifying an existing mass spectrometer.
H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locksArrangements for external adjustment of electron- or ion-optical components
H01J 49/26 - Mass spectrometers or separator tubes
Applicants have discovered new methods and apparatuses for determining the fractional composition of a component in a multi-component mixture using multivariate statistical analysis of the ultrasonic frequency profile. Applicants show the use of ultrasonic spectrophonometry to determine the fractional composition of a component in a 3-component solvent mixture comprising water, ethanol and methanol as well as determination of the fractional composition of certain contaminants in water. Applicants provide a method of determining a fractional composition of a component in a multi- component mixture comprising pulsing a mixture with a source of ultrasounds, detecting "non-linear" ultrasonic spectral data propagating through the mixture and computing the fractional composition of the component.
G01N 29/46 - Processing the detected response signal by spectral analysis, e.g. Fourier analysis
G01N 29/00 - Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic wavesVisualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
G01N 29/036 - Analysing fluids by measuring frequency or resonance of acoustic waves
G01N 29/30 - Arrangements for calibrating or comparing, e.g. with standard objects
52.
METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (USA)
MCGILL UNIVERSITY (Canada)
Inventor
Bowers, Cyril Y.
Coy, David H.
Hocart, Simon J.
Tannenbaum, Gloria S.
Abstract
The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18, wherein each of A11, A12, and A13 is independently absent, an amino acid, or an amino protecting group; each of A15-A16-A17, and A18 is independently absent or an amino acid; and A14 is a serine conjugated with a -C(O)C1-C20alky or a diaminopropionic acid conjugated with a -C(O)C1-C20alkyl group, provided that at least one of A11, A12, or A13 is present.
This invention is a game platform for the assessment and/or treatment of disorders of binocular vision, such as amblyopia. The game content is devised to maximize the possible therapeutic effects by leveraging advanced research in ophthalmology, as well as advanced display technology to render images independently to each eye. In particular, the game content engages both eyes at different levels of difficulty, forcing an amblyopic eye to work harder to regain its performance in the visual system. The invention herein described provides a mobile device, capable of interaction with an eye care specialist, for the assessment/treatment of binocular vision using innovative mechanisms for ensuring proper use thereof.
A61B 3/08 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing binocular or stereoscopic vision, e.g. strabismus
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
54.
Compositions and methods for preventing or treating an inflammatory response
The present invention relates to methods for modulating the inflammatory response of respiratory tract cells using an agent that increases ceramide levels in the cells of the respiratory tract.
A01N 37/18 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N, e.g. carboxylic acid amides or imidesThio-analogues thereof
A01N 31/08 - Oxygen or sulfur directly attached to an aromatic ring system
An information difference between a left eye image and a right eye image is adjustable to achieve binocular vision in a patient having a deficiency of binocular vision. A source of image pairs is used along with a dichoptic display system to present a selected one of the image pairs as a right eye image to a patient's right eye and a left eye image to a patient's left eye. The difference at which a patients achieves binocular vision is a measure of a level binocular vision health or function, and continued exposure to the image pairs is therapeutic. The difference can be adjusted during therapy, and restoration of regular binocular vision is possible.
A61B 3/08 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing binocular or stereoscopic vision, e.g. strabismus
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
The present invention relates to ionic liquids for use in chemical applications and capable of serving the dual function of solvent and liquid support. The ionic liquid lends itself to a method of synthesizing oligomers selected from the group consisting of oligopeptides, oligosaccharides and oligonucleotides, comprising contacting a first monomer unit with an ionic liquid at reaction conditions to provide an ionic liquid bound monomer unit; and contacting the ionic liquid bound monomer unit with at least one further monomer unit at reaction conditions to provide an ionic liquid bound oligomer comprising from 2 to 30 monomer units. The method lends itself to large scale manufacture of oligopeptides, oligosaccharides and oligonucleotides.
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
C07H 3/06 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
C07K 1/02 - General processes for the preparation of peptides in solution
C07K 1/04 - General processes for the preparation of peptides on carriers
The present invention pertains to new methods and apparatuses for the determination of pH of a fluid. Applicants have discovered that ultrasonic spectrophonometry (the study and measurement of acoustic spectra) can be used to distinguish conformational changes of albumin and red blood cells in response to pH. In accordance with the present invention, there is provided a method of determining the pH of a fluid based on a pH-dependent conformation of at least one fluid constituent comprising subjecting the fluid to an ultrasonic pulse; detecting ultrasonic spectral data of the fluid constituent resulting from the ultrasonic pulse; wherein the spectral data varies with pH; and then calculating pH from the spectral data.
Institut National de la Sante et de la Recherche Medicale (Inserm) (France)
McGill University (Canada)
Inventor
Bocquet, Arnaud
Eyer, Joël
Peterson, Alan
Abstract
The invention concerns a peptide derived from intermediate filaments and an intermediate filament fragment capable of altering tubulin polymerization and used for inhibiting cell proliferation, and more particularly for obtaining medicines designed to prevent or treat diseases involving cell proliferation, such as cancers for example.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
63.
Flavonoid dimers and methods of making and using such
Multidrug resistance (MDR) is a major problem in cancer chemotherapy. The best characterized resistance mechanism is the one mediated by the over-expression of drug efflux transporters, permeability-glycoprotein (P-gp), which pump a variety of anticancer drugs out of the cells, resulting in lowered intracellular drug accumulation. A series of flavonoid dimers are developed in this invention, which are linked together by linker groups of various lengths. These flavonoid dimers are found to be efficient P-gp modulators that increase cytotoxicity of anticancer drugs in vitro and dramatically enhance their intracellular drug accumulation. It is found that the flavonoid dimers of this invention is also useful in reducing drug resistance in treating parasitic diseases.
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 43/00 - Drugs for specific purposes, not provided for in groups
64.
APPARATUS AND METHOD FOR TREATING A CORTICAL-BASED VISUAL DISORDER USING TRANSCRANIAL MAGNETIC STIMULATION
For treating a cortical-based visual disorder, delivery of repetitive transcranial magnetic stimulation (TMS) to the visual cortex of a patient is used. A module for analyzing a patient's brain imaging data to generate coil position data for setting a position of a TMS coil, or a module for recording a position of phosphenes within a field of view experienced by the patient to generate coil position data for adjusting and/or setting a position of a TMS coil, or a module for recording the experience of phosphenes by the patient for a number of TMS events to determine parameters for repetitive TMS therapy is used.
The Royal Institution for the Association of Learning (Canada)
McGill University (Canada)
Inventor
Aouini, Sadok
Roberts, Gordon W.
Abstract
The present invention relates to a method and system for providing an analog Gaussian noise signal having the predetermined probability distribution function, bandwidth and center frequency. A band-limited digital noise signal indicative of a Gaussian noise signal having a predetermined Gaussian probability distribution function is ΣΔ modulated generating a pulse-density modulated 1-bit sequence representing a Gaussian noise signal having a predetermined probability distribution function, bandwidth and center frequency. Using an analog low-pass filter the pulse-density modulated 1-bit sequence is then converted into a respective analog Gaussian noise signal having the predetermined probability distribution function, bandwidth and center frequency. The method and system are successfully employed in numerous applications such as in histogram testing and probabilistic digitization.
An information content difference between a left eye image and a right eye image is adjustable to achieve binocular vision in a patient having a deficiency of binocular vision. A source of image pairs is used along with a dichoptic display system to present a selected one of the images pairs as a right eye image to a patient's right eye and a left eye image to a patient's left eye. The difference at which a patient achieves binocular vision is a measure of a level binocular vision health or function, and continued exposure to the image pairs is therapeutic. The difference can be adjusted during therapy, and restoration of regular binocular vision is possible.
A61B 3/032 - Devices for presenting test symbols or characters, e.g. test chart projectors
A61B 3/08 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing binocular or stereoscopic vision, e.g. strabismus
A system for detecting haemozoin in a sample, said system including a light source for exciting the sample with an optical signal to generate a non-linear optical response, and a detector for detecting the generated non-linear optical response from the excited sample. A method for detecting haemozoin in a sample, the method including exciting the sample with an optical signal to generate a non-linear optical response from the sample, and detecting the emitted non-linear optical signal from the excited sample.
G01N 21/63 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
G01N 33/483 - Physical analysis of biological material
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
68.
Treatment of ocular disease with inhibitors of alpha2 macroglobulin protein
The present invention relates to methods to treat glaucoma and glaucoma-related conditions through the regulation of changes in gene expression that are mediated by high intraocular pressure or α2 macroglobulin administration. Glaucoma, retinal ganglion cell (RGC) death and chronic ocular hypertension are treated using pharmaceutical compositions which comprise substances that inhibit the expression or activity of intraocular pressure-regulated early genes (IPREGs) or their gene products that are up-regulated by high intraocular pressure or α2 macroglobulin administration and/or which increase the expression or activity of IPREGs or their gene products that are down-regulated by high intraocular pressure or α2 macroglobulin administration. The invention also relates to methods of identifying an IPREG and methods to test for chronic ocular degeneration and the onset of RGC stress in an individual by measuring the expression level of IPREG proteins.
Disclosed herein is a matrix for inducing or enhancing osteoclast differentiation. The matrix comprises a material having an osteoclastogenic agent associated therewith, the agent being releasable from the material in an amount which is sufficient to induce or enhance osteoclast differentiation.
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
A61K 9/00 - Medicinal preparations characterised by special physical form
A61L 24/02 - Surgical adhesives or cementsAdhesives for colostomy devices containing inorganic materials
A61L 27/12 - Phosphorus-containing materials, e.g. apatite
Disclosed is a method for identifying an individual who has an altered risk for developing colorectal cancer comprising detecting a single nucleotide polymorphism (SNP).
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
A bioceramic endoprosthesis includes a reservoir or deposition of a bioactive substance, such as an angiogenic growth factor, that can provide a biological function, such as vascularization of the endoprosthesis. Such a bioceramic can be prepared by a low temperature direct rapid prototyping inkjet printing system and process. Such a direct inkjet printing process includes the following: applying a ceramic powder to a substrate; inkjet printing a binder solution onto the ceramic powder so as to form a bound ceramic; inkjet printing a bioactive substance solution onto the bound ceramic, wherein the bioactive substance is printed on the bound ceramic at the low temperature (e.g., room temperature or within +/- 10°C of 25°C); and repeating the process in order to form the bioceramic endoprosthesis.
A61J 3/06 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
A61K 9/24 - Layered or laminated unitary dosage forms
The invention provides methods for in vitro maturation of immature human oocytes. In one aspect, the invention provides a method for in vitro maturation of immature human oocytes, comprising the steps of: (a) inducing in a female human subject an increase in endogenous luteinizing hormone levels, said subject having not undergone an ovarian stimulation protocol prior to said inducing step; (b) obtaining from said subject an immature oocyte; and (c) culturing said oocyte until maturity.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
73.
GENETIC PREDICTORS OF RISK FOR TYPE 2 DIABETES MELLITUS
Methods of analyzing individuals at risk for the development of Type 2 diabetes mellitus (T2DM). Nucleic acids obtained from biological samples of individuals suffering from T2DM have been analyzed and SNPs associated with T2DM genes have been discovered. In addition, SNPs in linkage disequilibrium with T2DM genes are described.
A nanotube device comprises a gel matrix that includes microcapsules and functionalized nanotubes, or other functionalized nanostructures incorporated into said gel matrix. Pharmaceutical compositions and methods of treatment comprising same. The pharmaceutical compositions of the present invention enable the specific and targeted delivery of therapeutic agents such as DNA molecules, peptides, including antibodies, drug molecules (e.g. small organic molecules), while offering sufficient resistance towards mucus layer of the intestine and high concentrations of enzymes and other molecules found in the blood stream and the GI tract.
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
The present invention relates to a microvalve for controlling a fluid flow in a microchannel, to a microfluidic circuit using the microvalve, and to a manufacturing method thereof. The microvalve has a first electrode located on a portion of the microchannel, a second electrode over the microchannel and substantially aligned with the first electrode forming a membrane with substantially no resilience. In function, upon application of an electric force on the first and second electrodes, the second electrode draws nearer the first electrode, thus obstructing the microchannel. The microfluidic circuit comprises multiple microchannels and at least one microvalve affixed to one of the multiple microchannels, wherein the at least one microvalve is adapted to indirectly actuate a flexible valve adapted to regulate a flow of fluid in another one of a multiplicity of microchannels.
There is provided a method for predicting a clinical state of a subject based on image data obtained from a Volume Of Interest in the subject. The method comprise the establishment of a predictive model that relates image features and the future evolution of a clinical state.
There is provided a method for predicting a clinical state of a subject based on image data obtained from a Volume Of Interest in the subject. The method comprise the establishment of a predictive model that relates image features and the future evolution of a clinical state.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
The invention provides methods and compositions for use in the diagnosis and management of cancer, particularly breast cancer. The invention utilizes differential gene expression profiles in tumor associated stroma and normal stroma to compile a stroma derived prognostic predictor that classifies breast cancer patients according to clinical outcome. The application provides nucleic acids, antibodies, mircroarray chips and kits for use with the methods described in the application.
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
C07K 14/72 - ReceptorsCell surface antigensCell surface determinants for hormones
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C40B 40/06 - Libraries containing nucleotides or polynucleotides, or derivatives thereof
C40B 40/08 - Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
79.
AUGMENTING STEM CELL POPULATIONS BY MODULATING T-CELL PROTEIN TYROSINE PHOSPHATASE (TC-PTP)
A method of increasing stem cell expansion and isolating stem cells is disclosed. The method of expanding stem cells comprises incubating cells with an agent that inhibits T-cell protein tyrosine phosphatase (TC-PTP).
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The present invention relates to a process of producing a stable and densified pellet and the enhancement of phytochemical extraction from plant materials using pulsed electric field. The process is applied with a step involving pressing, wherein the pressing and the pulse electric field treatment can be accomplished in a unique treatment chamber.
The present invention relates to a decoding method and system for stochastic decoding of LDPC codes. Each encoded sample of a set of encoded samples is first scaled by a scaling factor proportional to a noise level of the set of encoded samples. Each of the scaled encoded samples is then converted into a corresponding probability. For each probability a corresponding probability message is the generated by encoding each probability as a sequence of digital bits. Each probability message is then provided to a respective node of a logic circuitry for stochastic decoding. The logic circuitry represents a factor graph of the parity check matrix of the LDPC code. Using the logic circuitry each probability message is processed for determining an estimated sequence of information bits. If an equality node is in a hold state a chosen bit is provided from a corresponding edge memory which is updated by storing output bits from the equality node when the same is in a state other than a hold state.
The present invention relates to a decoding method and system for stochastic decoding of LDPC codes. Each encoded sample of a set of encoded samples is first scaled by a scaling factor proportional to a noise level of the set of encoded samples. Each of the scaled encoded samples is then converted into a corresponding probability. For each probability a corresponding probability message is the generated by encoding each probability as a sequence of digital bits. Each probability message is then provided to a respective node of a logic circuitry for stochastic decoding. The logic circuitry represents a factor graph of the parity check matrix of the LDPC code. Using the logic circuitry each probability message is processed for determining an estimated sequence of information bits. If an equality node is in a hold state a chosen bit is provided from a corresponding edge memory which is updated by storing output bits from the equality node when the same is in a state other than a hold state.
An aqueous process for preparing alkylene carbonates from alkenes and carbon dioxide is described herein. The process comprises the reaction of alkenes with a bromine source, a base and carbon dioxide. The aqueous process can be rendered catalytic by using an oxidant capable of in situ conversion of bromide into bromine.
The present invention relates to an oral formulation to lower serum or hepatic lipid and triglyceride concentrations, hepatic inflammation and/or insulin resistance in a patient comprising live feruloyl esterase producing microorganisms alone or in association with a pharmaceutically acceptable carrier resistant to gastric conditions, and wherein the microorganisms are wild type, genetically modified, or combination thereof. The present invention is also directed to an oral formulation to lower serum or hepatic lipid and triglyceride concentrations, hepatic inflammation and/or insulin resistance in a patient, which comprises polymeric microcapsules containing live feruloyl esterase producing microorganisms in suspension in a pharmaceutically acceptable carrier, wherein said microcapsules are semipermeable and resistant to gastro-intestinal conditions, and wherein said microorganism are wild type, genetically modified, or combination thereof as well as methods of preventing or improving liver diseases and disorders and uses thereof.
A23G 9/36 - Frozen sweets, e.g. ice confectionery, ice-creamMixtures therefor characterised by the composition containing microorganisms or enzymesFrozen sweets, e.g. ice confectionery, ice-creamMixtures therefor characterised by the composition containing paramedical or dietetical agents, e.g. vitamins
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present invention provides oxepane nucleosides, oxepane nucleotides, modified oxepane nucleotides, oligonucleotides, methods for making and uses for modulating gene expression. The oxepane nucleoside having formula I : wherein B is a heterocyclic base, R0 is selected from the group consisting of hydrogen and alkyl having one to eight carbons, R1 through R10 are as described in the descriptions and mirror image enantiomers thereof.
C07H 19/10 - Pyrimidine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
C07H 19/20 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
86.
2'-DEOXY-2'-FLUORO-β-D-ARABINONUCLEOSIDE 5'-TRIPHOSPHATES AND THEIR USE IN ENZYMATIC NUCLEIC ACID SYNTHESIS
The invention relates to arabinose modified nucleoside 5' triphosphates and to the biosynthesis and amplification of oligonucleotides containing and/or from templates containing arabinose modified nucleosides. The invention further relates to methods of generating modified oligonucleotide libraries for use in selection strategies, such as SELEX. The arabinose modified oligonucleotides of the invention are useful for modulating target nucleic acid expression, such as RNA.
C07H 19/20 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
C07H 19/00 - Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radicalNucleosidesMononucleotidesAnhydro derivatives thereof
C07H 19/10 - Pyrimidine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
C40B 50/06 - Biochemical methods, e.g. using enzymes or whole viable microorganisms
A control system for a robotic device maneuverable in at least a liquid medium, the system having at least one visual sensor retrieving an image of the device's environment, an image analyzing module receiving the image, determining a presence of an object of a given type therein and analyzing at least one property of the object, a motion calculator determining a desired motion of the device based on the property, and a controller operating a propulsion system of the device to obtain the desired motion. Also, a legged robotic device having a control system including at least one sensor providing data about an environment of the device, the control system using sensor data to determine a desired motion of the device, determining a corresponding required leg motion of each of the legs to produce the desired motion and actuating the legs in accordance with the corresponding required leg motion.
B63H 21/22 - Use of propulsion power plant or units on vessels the propulsion power units being controlled from exterior of engine room, e.g. from navigation bridgeArrangements of order telegraphs
88.
FUSION PROTEINS AND METHODS FOR MODULATION OF IMMUNE RESPONSE
A fusion protein comprising GM-CSF and IL-15 is described. The fusion protein has unexpected immune suppressive properties and is useful in a variety of therapeutic applications.
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A drill bit, system and method for penetrating a material such as a mineral bearing rock or the like is disclosed. The system comprises a drill bit comprising a cutting face comprising at least one cutting tool, an emitter of microwaves positioned behind the cutting face, wherein at least a portion of the microwaves are emitted in a direction away from the cutting face, and a reflector for directing the portion to the cutting face. In operation the emitted microwaves irradiate the material prior to the irradiated material being removed by the at least one cutting tool.
B01J 19/12 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor employing electromagnetic waves
E21C 35/00 - Details of, or accessories for, machines for slitting or completely freeing the mineral from the seam, not provided for in groups , or
An instrumented ball for collecting data in an industrial mill comprising a durable sphere defining an enclosed cavity and having a substantial thickness, the sphere manufactured from a resilient material able to withstand pressures exerted by a working industrial mill, electronics disposed in the cavity comprising: a plurality of devices for sensing physical conditions inside the mill, wherein each of the sensing devices outputs a series of sensed values, the devices comprising at least an accelerometer, a gyroscope, a thermocouple, a microphone and a wear sensor, a memory for storing the sensed values, and a communication port for transmitting the sensed values to an external device located outside of the mill, and a power source disposed in the cavity for powering the electronics.
G01C 23/00 - Combined instruments indicating more than one navigational value, e.g. for aircraftCombined measuring devices for measuring two or more variables of movement, e.g. distance, speed or acceleration
B02C 17/18 - Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls Details
B02C 23/00 - Auxiliary methods or auxiliary devices or accessories specially adapted for crushing or disintegrating not provided for in groups or not specially adapted to apparatus covered by one only of groups
B02C 25/00 - Control arrangements specially adapted for crushing or disintegrating
G01D 21/02 - Measuring two or more variables by means not covered by a single other subclass
G01P 15/18 - Measuring accelerationMeasuring decelerationMeasuring shock, i.e. sudden change of acceleration in two or more dimensions
G01K 7/02 - Measuring temperature based on the use of electric or magnetic elements directly sensitive to heat using thermoelectric elements, e.g. thermocouples
G01N 17/00 - Investigating resistance of materials to the weather, to corrosion or to light
H04Q 9/00 - Arrangements in telecontrol or telemetry systems for selectively calling a substation from a main station, in which substation desired apparatus is selected for applying a control signal thereto or for obtaining measured values therefrom
91.
FIBROUS CALCIUM PYROPHOSPHATE PARTICLES AND METHODS OF MAKING AND USING SAME
Fibrous calcium pyrophosphate particles with a unique fibrous nanostructure are disclosed. The invention includes a composition, comprising fibrous particles, wherein the fibrous particles include fibers and the fibers include calcium and pyrophosphate. Also included are methods for making calcium pyrophosphate particles wherein solutions of calcium salt and pyrophosphate salt are combined to form the particles. Pharmaceutical compositions and methods for treating a patent using the disclosed particles are also described.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A synthetic monodisperse hemozoin crystals preparation, compositions and methods of preparation thereof, are described. Also described are uses thereof, including use as an adjuvant, use in an immunogenic or vaccine composition, use for enhancing or inducing immunogenicity, and corresponding prevention or treatment of disease or infection.
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Disclosed is a method for identifying an individual who has an altered risk for developing colorectal cancer comprising detecting a single nucleotide polymorphism (SNP).
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
The present invention relates to an oral formulation comprising a microcapsule containing bacteria and a fermented milk carrier. There is also provided a method of medical treatment of an inflammatory gastrointestinal disease or disorder in a subject in need thereof, comprising detecting the presence of inflammatory gastrointestinal disease or disorder in the subject, wherein if inflammatory gastrointestinal disease or disorder is detected, then administering the formulation of the present invention to the subject.
Hybrid molecules comprising a vitamin D receptor agonist moiety and an HDAC inhibitor moiety are described herein The HDAC inhibitor moiety can be modelled after an HDAC inhibitor selected from the group consisting of t꧀chostatm A, sodium butyrate, valproic acid, N- acetyldmalme and suberoylamlide hydroxamic acid These hybrid molecules can be used in the manufacture of medicaments for the treatment of bacterial infections, cancer, inflammation or auto-immune diseases or for the induction of wound healing Specific hybrid molecules of the present invention have the following structures.
C07C 401/00 - Irradiation products of cholesterol or its derivativesVitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
A61K 31/59 - Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems
96.
IDENTIFICATION OF CRMP4 AS A CONVERGENT REGULATOR OF AXON OUTGROWTH INHIBITION
The present invention relates to the identification of the cytosolic phosphoprotein CRMP4b as a protein that physically and functionally interacts with RhoA to mediate neurite outgrowth inhibition. siRNA-mediated knockdown of CRMP4 promotes neurite outgrowth on myelin substrates indicating a critical role for CRMP4 in neurite outgrowth inhibition. Disruption of CRMP4b-RhoA binding with a competitive inhibitor attenuates neurite outgrowth inhibition on myelin and aggrecan substrates. Stimulation of neuronal growth cones with Nogo leads to co-localization of CRMP4b and RhoA at discrete regions within the actin-rich central and peripheral domains of the growth cone indicative of a potential function in cytoskeletal rearrangements during neurite outgrowth inhibition. Together these data indicate that a RhoA-CRMP4b complex forms in response to inhibitory challenges in the growth cone environment and regulate cytoskeletal dynamics at distinct sites necessary for axon outgrowth inhibition. Competitive inhibition of CRMP4b-RhoA binding suggests a novel, highly specific therapeutic avenue for promoting regeneration following CNS injury.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The present invention relates to the use of polymers as contrast agents for ultrasounds. The idea is to have a molecular imprint in the polymer that is specific for a given molecule or analyte. When that molecule binds to the polymer it induces a conformational change that results in an increase in the ultrasound signal, referred to as a target-bound state. The method can also be used for example for quantitative measurements of analytes.
The present invention relates to methods for modulating the inflammatory response of respiratory tract cells using an agent that increases ceramide levels in the cells of the respiratory tract.
A01N 37/18 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N, e.g. carboxylic acid amides or imidesThio-analogues thereof
A method and reactor for in-situ synthesis, stabilization and dispersion of nanoparticles in a organic host fluid, and nanofluids containing nanoparticles that are coated in-situ with a surface layer compatible with the organic host fluid.
C23C 16/503 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating using electric discharges using DC or AC discharges
B01J 19/24 - Stationary reactors without moving elements inside
A method of differentiating between first diffuse large cell B lymphoma (DLCBL) cells and second DLCBL cells, known to respond to CD40 mediated apoptosis, based on differences in expression of one or more genes or a profile of genes and a method to differentiate between CD40 sensitive and CD40 resistant DLCBL cells based on the differences in gene expression of recombination activating gene 1(RAG 1), pre-B lymphocyte gene 1 (VPREB 1), lymphocyte specific protein tyrosine kinase (LCK) and VAV 1 oncogene (VAV 1).
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
